Published on : Oct 27, 2017
Albany, New York, October 27, 2017: Diabetes mellitus is one of the most common types of diabetes that affects millions of people worldwide. Nearly 90 percent of diabetes patients all over the world have type 2 diabetes, which makes it the most common of all. This has led to a strong commercial interest in the development of T2DM therapeutics. T2DM treatment has been reformed in the previous decade, especially with the increased use of novel therapies. To pour more light on the latest therapeutic methods in T2DM, a new study titled “Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth” has been prepared by analysts, which is now broadcasted to the wide repository of Market Research Hub (MRH). This 202-pages research study offers comprehensive information about the therapeutic strategies, products, and companies that dominate the current marketed product landscape and recognize gaps and areas of unmet need.
Analysts find that the prevalence of the disease has risen rapidly in recent decades in the considered South-East Asia countries, primarily as a result of rising obesity, a major risk factor for type 2 diabetes mellitus (T2DM). This has resulted in a large and competitive market landscape. Hence, current market of type 2 diabetes mellitus therapeutics in South-East Asia is large and diverse, comprising several drug classes, including generic and branded drugs. Over the 2016-2023 forecast period, the T2DM therapeutics market in South-East Asia is expected to increase in value at a CAGR of 6.3%, from $1.92 billion to over $2.96 billion, finds the study.
In the first part, readers will be able to understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options. Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia. Chronic hyperglycemia is connected with the long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels, therefore effective treatment methods are essential. People with type 2 diabetes require regular monitoring and ongoing treatment to maintain normal or near-normal blood sugar levels. Although diabetes cannot be cured, it can be treated successfully. The study further adds the marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies.
The study further matches treatment usage patterns, annual therapy costs, and market growth projections for South-East Asia Markets including South Korea, Singapore, Taiwan, Vietnam, Malaysia, the Philippines, Thailand, and Indonesia. Moving further, the study throws lights on the analysis of clinical trials since 2006 and identified that the failure rates of T2DM molecules were highest in Phase III, at 62.1%, with the overall attrition rate for T2DM standing at 88.3%. Besides, the research identifies key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1354596
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org